Deal facts
- Buyer
- Azenta, Inc.
- Target
- SynPlexity Inc.
- Deal value
- Not disclosed
- Announced
- 30 October 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- Not stated
Sources
Azenta, Inc. acquired SynPlexity Inc. on October 28, 2026, by entering into a Stock Purchase Agreement with SynPlexity, its stockholders and other parties. Under the agreement, Azenta acquired all of SynPlexity's issued and outstanding capital stock. The acquisition closed concurrently with execution of the agreement, so signing and completion fell on the same day. Azenta disclosed the deal in a Form 8-K and said it issued a press release announcing the acquisition on October 30, 2026.
The filing describes SynPlexity as a DNA assembly technology company. Its products and services center on large, multiplexed gene libraries for functional screening, drug discovery, therapeutics and other applications. Azenta said the acquisition adds technology and expertise that it intends to integrate into its GENEWIZ synthesis portfolio.
The 8-K does not state a purchase price or the form of consideration for SynPlexity. Its forward-looking statements, which cover both the acquisition and the Elegen arrangements, mention potential contingent payments without attributing them to either transaction or giving an amount or terms.
Azenta reported the SynPlexity purchase alongside, but separately from, two agreements signed the same day with Elegen Corp.: a Technology, Equipment and License Agreement and a Master Services and Supply Agreement. The filing states that the acquisition and the Elegen arrangements are separate transactions, each intended to support the continued development of Azenta's DNA synthesis capabilities. The Elegen license has an initial term of five years, and the capital deployment figures in the filing (expected to range from approximately $32 million to approximately $71 million) relate to the Elegen agreements, not to the SynPlexity purchase.
Deal timeline
1 update- CompletedClosed
Azenta, Inc. completes acquisition of SynPlexity Inc.
Item 1.01. Entry into a Material Definitive Agreement . On October 28, 2026, Azenta, Inc. (“Azenta” or the “Company”) entered into a Technology, Equipment and License Agreement (the “License Agreement”) and a Master Services and Supply Agreement (the “Supply Agreement” and, together with the License Agreement, the “Elegen Agreements”) with Elegen Corp. (“Elegen”). The Elegen Agreements form an int
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
Azenta, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive